Kepler Capital Remains a Hold on TotalEnergies SE (TTE)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Hodee is a 5-star analyst with an average return of 18.4% and a 62.82% success rate. Hodee covers the Energy sector, focusing on stocks such as TotalEnergies SE, Shell (UK), and BP p.l.c..
TotalEnergies SE has an analyst consensus of Strong Buy, with a price target consensus of €61.75.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
28 minutes ago
- Business Insider
Penny Stock Plug Power (PLUG) Is About to Report Q2 Earnings Tomorrow. Here Is What to Expect
Plug Power (PLUG), a provider of hydrogen fuel cell solutions, will release its Q2 results tomorrow, August 11. This penny stock has fallen over 29% year-to-date and 22% over the past year due to poor financial performance, continued losses, and weak investor sentiment in the hydrogen and clean energy sector. Wall Street analysts expect the company to report a loss of $0.15 per share for Q2 2025, versus a $0.36 per share loss reported in the prior-year quarter. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Meanwhile, analysts expect revenues of $158.04 million, reflecting a 10% year-over-year increase, according to data from the TipRanks Forecast page. Importantly, Plug Power has missed the consensus EPS estimates in all of the last nine quarters. Analysts' Views on PLUG Ahead of Q2 Results Ahead of the Q2 print, Jefferies analyst Julien Dumoulin Smith raised his price target on the stock from $0.90 to $1.60 but kept a Hold rating. The 4-star analyst said that even though the new clean energy bill is now in place, it's still hard to be confident about renewable energy stocks. The bill, called the 'One Big Beautiful Bill Act,' offers extended tax credits for clean electricity and hydrogen projects. These credits are meant to support growth and investment in renewable energy. Meanwhile, H.C. Wainwright analyst Amit Dayal reiterated a Buy rating and $3 price target on Plug Power, noting that recent changes in clean energy incentives, especially the extension of hydrogen tax credits, are positive for the company's long-term outlook. Options Traders Anticipate a Large Move Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry; the Options tool does this for you. Indeed, it currently says that options traders are expecting a 17.22% move in either direction. Is Plug Power Good Stock to Buy? The stock of Plug Power has a consensus Hold rating among 18 Wall Street analysts. That rating is currently based on four Buy, 10 Hold, and four Sell recommendations issued in the past three months. The average PLUG price target of $1.57 implies 3.97% upside from current levels.
Business Insider
28 minutes ago
- Business Insider
4 Economic Events That Could Affect Your Portfolio This Week, August 11-15, 2025
Stocks rebounded on Friday, closing the week firmly in the green – the market's third winning week out of the last four. The S&P 500 (SPX) rallied for its strongest week since late June, closing on the brink of a record after gaining 2.43%. The Dow Jones Industrial Average (DJIA) finished the week up 1.35%. Meanwhile, the Nasdaq-100 (NDX) surged by 3.73%, reaching a new record. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. After the prior week's pull‑back, investors bought the dip again, demonstrating conviction in the rally's viability – grounded in solid fundamentals. Around 90% of S&P 500 companies have reported Q2 earnings, with 81% beating expectations – the best since Q3 2023. In tech, more than 90% have exceeded forecasts. These strong results have prompted analysts to lift Q3 earnings expectations. Despite ongoing tariff-related and broader macro uncertainties, the U.S. corporate sector remains resilient – with expectations that this strength will persist, assuming the economy holds. Companies' managements and boards are reflecting that confidence through share repurchases. In July alone, U.S. companies announced a record $166 billion in stock buybacks – the highest for any July on record, and year-to-date repurchases now total nearly $926 billion, exceeding the previous record. IPO activity is also robust – as of August 5, 2025, there have been 202 IPOs in the U.S., up 80% over the same period last year. The average effective U.S. tariff rate is at its highest level since the Great Depression – yet today's economy and corporate sector are far more advanced and adaptive. Tariffs have already nudged prices upward, and a short-term inflation bump is expected throughout this year and next. Still, the U.S. economy – dynamic and resilient – is adjusting. Companies are shifting supply chains, and because tariffs were announced ahead of time, they had ample time to prepare. Some sectors may even benefit from increased domestic investment and reshoring. On the household front, while tariffs could dent purchasing power via higher prices, the impact should be limited and temporary, not a sustained driver of inflation. Future trade agreements are expected to ease tensions and help contain inflation and growth risks. Last week's rally underscores U.S. resilience — stocks advanced even as Trump's tariff rollout accelerated. In fact, some signs of economic softness may have aided the rally, by heightening odds of a 0.25% rate cut in September. With valuations rich but still not technically overbought, a rate cut could inject fresh momentum heading into the Q3 earnings season. Nevertheless, analysts broadly agree that the path ahead may remain choppy, with trade, macro, and geopolitical developments likely to test investor resolve. Four Economic Events Here are four key economic events that could affect your portfolio this week. For a full listing of additional economic reports, check out the TipRanks Economic Calendar. » July CPI and CPI ex. Food and Energy (Core CPI) – Tuesday, 08/12 – The Consumer Price Index (CPI) is one of the two key measures of inflation (the other being the Personal Consumption Expenditures index, or PCE). Policymakers, businesses, and consumers closely monitor the CPI report, as it reflects price trends across the economy, shapes consumer spending and business sentiment, and directly influences the Federal Reserve's interest rate decisions. » July Producer Price Index (PPI) and PPI ex. Food and Energy – Thursday, 08/14 – This report reflects input costs for producers and manufacturers. Since the PPI measures the cost of producing consumer goods – which ultimately affects retail prices – it is viewed as a leading indicator of inflationary pressures. As such, it often foreshadows the following month's CPI and plays a critical role in shaping inflation expectations among policymakers. » July Retail Sales – Friday, 08/15 – This report indicates how much consumers are spending on durable and non-durable goods. Retail Sales is a leading indicator of economic health, offering insight into the current quarter's economic growth and the inflationary pressures stemming from consumer demand. » August Michigan Consumer Sentiment Index and UoM 5-year Consumer Inflation Expectations (preliminary readings) – Friday, 08/15 – These reports summarize the findings of a monthly survey measuring consumer confidence and long-term inflation expectations in the U.S. Consumer confidence directly affects spending, which accounts for roughly 70% of U.S. GDP. The inflation expectations component is also factored into the Federal Reserve's Index of Inflation Expectations.
Business Insider
44 minutes ago
- Business Insider
‘Time to Double Down,' Says Top Investor About Novo Nordisk Stock
It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company's share price has tumbled some 60% over the past twelve months. Though Novo Nordisk remains the dominant player in the burgeoning GLP-1 market, worries over a complex regulatory environment, lowered guidance, and increasing competition, among other concerns, have whittled away some of its support. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. And yet, the company's Q2 2025 earnings call last reflected rising sales of 18% during the first half of the year, increased operating profits of 29% for the first six months as well, and advancements with strategic R&D initiatives including an oral weight loss medicine. The market responded with a warmth that has been missing, and NVO's share price has increased by double digits since the earnings call. Top investor James Foord thinks a turnaround is indeed beckoning. 'The recent stock correction presents a rare long-term buying opportunity, supported by a strong pipeline, manufacturing expansion, and international momentum,' asserts the 5-star investor, who is among the top 2% of TipRanks' stock pros. The investor notes that the company succeeded in delivering strong numbers in Q2, with GLP-1 drugs leading the way. While sales for Ozempic – used to treat Type 2 diabetes – jumped by 35%, the Wegovy weight loss drug saw its sales increase by 67%. And it's not just the North American market which is gaining steam, points out Foord. Japan experienced a 91% increase in GLP-1 drugs in Q2. It is this dominance in the GLP-1 market which gives Foord plenty of bullish confidence in NVO going forward – especially as Wegovy aims for a 2026 tablet form. 'Novo has shown superior performance in their latest pill version of Wegovy versus Lily, and this is very encouraging,' adds Foord. With the company spending billions of dollars to increase production capabilities, including in North Carolina, and the potential for GLP-1 drugs to be used for additional morbidities such as Alzheimer's and cardiovascular disease, the investor predicts NVO is on the road to recovery. 'With new facilities coming online, oral drugs in development, and global demand still exploding, I see NVO not only rebounding but potentially doubling in the next few years,' concludes Foord. 'I'm buying more.' No surprise here, Foord is rating NVO a Strong Buy. (To watch James Foord's track record, click here) Though slightly more tempered, Wall Street is also optimistic about NVO. With 2 Buy ratings and 3 Holds, NVO enjoys a Moderate Buy consensus rating. Its 12-month average price target of $71.75 has an upside north of 40%. (See NVO stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
